002437.SZ SHZ
Harbin Gloria Pharmaceuticals Co., Ltd
1W: -3.4%
1M: -16.5%
3M: +24.1%
YTD: +4.9%
1Y: +2.8%
3Y: +78.9%
5Y: +43.1%
¥3.65 ($0.54)
+0.18 (+5.19%)
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$411M
+49.9% ▲
5Y CAGR: -7.6%
Capital Expenditures
$63M
-112.3% ▼
5Y CAGR: +5.4%
Free Cash Flow
$348M
+42.3% ▲
5Y CAGR: -9.1%
Dividends Paid
$9M
+78.6% ▲
Buybacks
$1M
+0.0% ▲
Net Change in Cash
-$230M
+55.7% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $409M | $54M | -$290M | $129M | $243M |
| Depreciation & Amort. | $149M | $144M | $130M | $104M | $92M |
| Stock-Based Comp. | $40M | $0 | $0 | $0 | $0 |
| Change in Working Capital | -$167K | -$23M | -$25M | $13M | $35M |
| Other Non-Cash Items | -$705M | $99M | $446M | $28M | $41M |
| Operating Cash Flow | $13M | $274M | $262M | $274M | $411M |
| — Investing Activities — | |||||
| Capital Expenditures | -$44M | -$35M | -$33M | -$30M | -$63M |
| Acquisitions (Net) | $1.0B | $75M | $3M | $732K | -$3M |
| Investment Purchases | -$1.3B | -$1.5B | -$695M | -$405M | -$30M |
| Investment Sales | $1.3B | $1.6B | $462M | $515M | $18M |
| Other Investing | $8M | $3M | $40M | $14M | $19M |
| Investing Cash Flow | $1.0B | $81M | -$224M | $94M | -$59M |
| — Financing Activities — | |||||
| Net Debt Issuance | -$1.3B | $0 | -$1.7B | -$786M | -$675M |
| Stock Repurchased | $0 | $0 | $0 | $0 | -$1M |
| Dividends Paid | -$134M | -$71M | -$69M | -$44M | -$9M |
| Other Financing | -$216M | $433M | $1.5B | -$59M | $102M |
| Financing Cash Flow | -$1.7B | $362M | -$213M | -$889M | -$583M |
| Net Change in Cash | -$639M | $715M | -$163M | -$520M | -$230M |
| Cash End of Period | $678M | $1.4B | $1.2B | $711M | $481M |
| Free Cash Flow | -$31M | $240M | $229M | $245M | $348M |